Milwaukee Capital Partners Acquires MPP Group in All-Cash Transaction
Wisconsin Eagle/10308658

MEQUON, Wis., June 23, 2025 ~ Milwaukee Capital Partners, LLC (MCP) has made a significant move in the investment landscape with their recent acquisition of MPP Group LLC. The acquisition, effective May 1, 2025, was joined by an investment from Concordia University Ventures (CU Ventures), led by Daniel Sem.

MPP Group will continue to operate from its headquarters in the Mequon Technical Park, a rapidly growing area known for its scientific and soft manufacturing excellence. With this acquisition, MPP Group plans to expand its investment interests into pharmaceutical contract research and development.

Thomas Kintis, Managing Partner of MCP, will serve as Board Chairman and Senior Advisor for MPP Group. Benjamin Nelson, Ph.D., the current President and Head of Product Development at MPP Group, will continue to lead the company's ongoing business interests and daily operations.

MCP is a well-known entity in private equity investment with a strong track record of advancing emerging technologies. Their strategic decisions have always been driven by a vision for growth and innovation, making them a key player in the investment landscape. With this latest acquisition, MCP is poised to further expand their portfolio and drive significant advancements within the pharmaceutical industry.

More on Wisconsin Eagle

• Speranza Dental Implant Centers Opens Their First Location
• WWSG Announces Exclusive Speaking Partnership with Former Australian Prime Minister Tony Abbott
• Aidaptive and BizCor Expand Inhabit Partnership with Native Enterprise-Grade Search for Streamline Customers
• Pikmykid Partners with Vivi to Enhance School Emergency Communication and Safety
• AI Meets Cybersecurity: IQSTEL and Cycurion Take Aim at $500 Billion Market Opportunity

The acquisition of MPP by MCP marks a new chapter in the company's 10-year history. It will provide significant cash infusion to advance specialized analytical services and additional capital investments throughout the organization's growth.

According to Thomas Kintis, "with a growing focus on bringing pharmaceutical development and manufacturing back to the US, we believe that MPP is well-positioned to partner with pharma and biotech companies both domestically and internationally."

MPP Group specializes in providing contract analytical services and product research and development. Their primary focus is on developing formulations for injectable drug products. Their range of services includes analytical development and validation, formulations development, container/closure screening, and elemental impurities analysis/risk assessments.

The location of MPP Group in Southeastern Wisconsin provides access to a highly talented pool of scientists and engineers. This allows for access to expertise in advanced sciences, drug development, and manufacturing. The facility is also conveniently located near some of the Midwest's top universities and major airports.

More on Wisconsin Eagle

• N A S D A Q Compliance Achieved Following Active Trading and Financing, UAE Acquisition & Major Brand Events: Lottery.com Inc., (N A S D A Q: LTRY)
• New Frontier Aerospace Successfully Tests Its Revolutionary Mjölnir Rocket Engine
• Profiting from Elder Harm: The Push to End Psychiatric Drugging in Nursing Homes
• LET Mining launches zero-cost cloud mining, daily rewards + referral double benefits
• Veteran-Owned Small Business Trapped in Amazon Seller Catch-22 Over Fraudulent FBA Partner

MPP Group was established in 2016 by Michal A. Major, Ph.D., the former president and founder of Cambridge Major Laboratories. The company emerged on the CRO front with a focus on providing access to emerging pharma and biotech companies with limited or non-existent testing and development capabilities. Today, MPP Group prides itself on forming careful partnerships that demand full attention from the team, honest engagement, and timely delivery of key objectives at a personalized level - something not commonly experienced in the challenging space of contract services.

The FDA inspected and approved site spans over 35,000 square feet and consists of five laboratories equipped with qualified and validated instrumentation. It also includes over 12,000 square feet of available space for future expansion for sterile manufacturing.

For more information about MCP and investment opportunities, please contact Thomas Kintis at [insert contact information]. For information about MPP Group's services, please contact Ben Nelson at [insert contact information]. For information about CU Ventures, please contact Daniel Sem at [insert contact information].

---

Show All News | Report Violation